George Cox, president of Bolder BioTechnology, said: “We are grateful to receive continued support from the National Institute of Neurological Disorders and Stroke (NINDS) for our long-acting beta interferon program. With previous funding from NINDS we developed a novel beta interferon analog that has a longer duration of action and more potent biological activity than existing beta interferon products in animals.
“The new grant award will be used to perform preclinical studies required by the FDA for filing an investigational new drug application to begin testing our long-acting beta interferon analog in people.”